4 results about "Amyloid β peptide" patented technology

Provided is a pharmaceutical combination for preventing or treating a neurodegenerative disease. The pharmaceutical combination includes a first agent being an insulin sensitizer and a second agent being a lipid metabolism modulator. Also provided is a method for preventing or treating a neurodegenerative disease in a subject in need thereof by administering the first agent and the second agent to the subject, thereby reducing the visceral adiposity and the accumulation of amyloid β peptides in the subject.

The invention relates to a method of enriching a sample for amyloid β peptides, comprising (i) contacting the sample with a solid support having thereon an immobilised anti-amyloid β peptide antibody;

A method of enriching a sample for amyloid β peptides, said method comprising: (i) contacting the sample with a solid support having immobilised thereon an anti-amyloid β peptide antibody; (ii) washing said solid support with a washing solution which has a pH between 10.5 and 10.7; (iii) applying an elution solution which has a pH between 10.5 and 10.7 to said solid support; and (iv) collecting the eluted sample.

The present invention relates to a method for preparing a plasma sample comprising amyloid beta peptides for analysis by mass spectrometry, comprising the steps of:a) contacting said plasma sample with a denaturing agent, b) performing a first solid phase extraction step on the solution obtained in step a) to recover a first eluate, c) performing a second solid phase extraction step on said first eluate obtained in step b) to recover a second eluate, and d) drying said second eluate obtained in step c) and processing it for analysis by mass spectrometry, wherein the solution obtained in step d) comprises intact amyloid beta peptides Aβ40 and Aβ42.